What Lies Ahead For Cassava Sciences (SAVA) In Q4 Earnings?

By Zacks Investment ResearchStock MarketsMar 01, 2020 10:26PM ET

www.investing.com/analysis/what-lies-ahead-for-cassava-sciences-sava-in-q4-earnings-200512479

What Lies Ahead For Cassava Sciences (SAVA) In Q4 Earnings?

By Zacks Investment Research | Mar 01, 2020 10:26PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

AVEO

0.00%

Add to/Remove from Watchlist

SAVA

-4.98%

Add to/Remove from Watchlist

CCXI

+0.00%

Add to/Remove from Watchlist

HARP

+0.00%

Add to/Remove from Watchlist

At fourth-quarter 2019 earnings conference, we expect investors to focus on Cassava Sciences, Inc.’s (NASDAQ:SAVA) updates related to its lead candidate PT-125, a proprietary small molecule drug, being developed for the treatment of Alzheimer’s disease (AD).

In the last reported quarter, Cassava Sciences delivered a positive surprise of 75.00%.

Shares of Cassava Sciences have skyrocketed 367.5% in the past year versus the industry’s decline of 15.2%.

Let’s see, how things are shaping up for this announcement.

Major Updates on Q4 Earnings Call

In absence of a marketed product in the company’s portfolio, investors’ focus will be on the updates related to Cassava Sciences’ pipeline development. Cassava Sciences was earlier known as Pain Therapeutics.

Investors will be keen to get the latest details on Cassava Sciences’ lead candidate PT-125, which is being developed in a mid-stage study for the treatment of AD. In September 2019, the company reported positive results from a phase IIa study, data from which demonstrated that all evaluable Alzheimer’s patients showed a biomarker response to PTI-125.

Meanwhile, Cassava Sciences initiated a phase IIb study on PTI-125 in Alzheimer’s patients with funding provided by National Institutes of Health (NIH). The enrollment in this study was completed this January with top-line data expected in mid-2020.

We expect management to provide a detailed update on the same during the upcoming investor’s call.

Moreover, Cassava Sciences is developing PTI-125DX, a simple blood test to detect or confirm if a person has Alzheimer’s disease. The company seeks to gain regulatory approval for PTI-125 for AD and PTI-125Dx for the diagnosis of AD. Notably, its Alzheimer’s program gains financial support from NIH.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Cassava Sciences this season. The right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: Cassava Sciences has an Earnings ESP of 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 14 cents per share.

Zacks Rank: Cassava Sciences carries a Zacks Rank #3, which increases the predictive power of ESP. However, the 0.00% ESP makes surprise prediction difficult.

Cassava Sciences, Inc. Price and EPS Surprise

Pain Therapeutics Price and EPS Surprise

Cassava Sciences, Inc. price-eps-surprise | Cassava Sciences, Inc. Quote

Stocks That Warrant a Look

Here are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around.

ChemoCentryx, Inc. (NASDAQ:CCXI) has an Earnings ESP of +14.18% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has an Earnings ESP of +28.04% and is Zacks #3 Ranked.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) has an Earnings ESP of +13.51% and is a #3 Ranked stock.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report

ChemoCentryx, Inc. (CCXI): Free Stock Analysis Report

Pain Therapeutics (SAVA): Free Stock Analysis Report

Harpoon Therapeutics, Inc. (HARP): Free Stock Analysis Report

Original post

Zacks Investment Research

Why Tesla Stock Has Fallen Over 45% Since December 2024 By Timothy Fries - Mar 10, 2025 7

Tesla (NASDAQ:TSLA) (NYSE: TSLA), the electric vehicle giant, has recently experienced a significant drop in its stock value, which has fallen nearly 45% since December. This...

Gold Miners Have Been Cast Aside—But Smart Money May Be Rotating in By Gary Tanashian - Mar 10, 2025

Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...

S&P 500, Russell 2000 Break Key Trendlines - Deeper Correction Ahead? By Declan Fallon - Mar 10, 2025

I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.65%

Apr 17, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	41,901.5	-10.8	-0.03%
US 500	5,598.9	-15.8	-0.28%
Dow Jones	41,911.71	-890.01	-2.08%
S&P 500	5,614.56	-155.64	-2.70%
Nasdaq	17,468.32	-727.90	-4.00%
S&P 500 VIX	27.86	+4.49	+19.21%
Dollar Index	103.685	-0.268	-0.26%

Crude Oil WTI	65.82	-0.21	-0.32%
Brent Oil	69.18	-0.10	-0.14%
Natural Gas	4.435	-0.026	-0.58%
Gold	2,894.80	-4.60	-0.16%
Silver	32.513	-0.017	-0.05%
Copper	4.6655	+0.0200	+0.43%
US Soybeans	1,011.25	-2.00	-0.20%

U.S. 10Y	4.180	-0.033	-0.78%
U.S. 30Y	4.508	-0.031	-0.68%
U.S. 5Y	3.921	-0.053	-1.33%
U.S. 3M	4.414	+0.120	+2.79%
US 10Y T-Note	111.77	+0.48	+0.44%
Euro Bund	128.08	+0.25	+0.20%
10-2 Yield Spread	31.32	+4.15	+15.27%

Apple	227.48	-11.59	-4.85%
NVIDIA	106.98	-5.71	-5.07%
Alphabet A	165.87	-7.99	-4.60%
Tesla	222.15	-40.52	-15.43%
Amazon.com	194.54	-4.71	-2.36%
Netflix	866.68	-24.43	-2.74%
Meta Platforms	597.99	-27.67	-4.42%

What Lies Ahead For Cassava Sciences (SAVA) In Q4 Earnings?

Related Articles